Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
French open-label extension study of canakinumab in SJIA patients from CACZ885G2301E1
2014-002872-95Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA) and juvenile idiopathic arthritis (JIA), sponsored by Novartis. Started Jun 2015; status: completed.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2014-002872-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002872-95.